Dr Andrew Rut discusses why monitoring drug safety will be key during COVID-19 developments, the lessons that can be learned from previous experience such as dengvaxia and the responsibility of the pharma community to build a body of scientific evidence through robust and reliable studies.
“If we fail to provide sufficient evidence to support the benefit-risk of treatments and vaccinations, then we expose global populations to three potential risks:
- providing ineffective medicines to large populations
- providing effective medicines that also cause significant harm when given to large populations
- providing ineffective medicines that also cause significant harm to populations”
Read the full article in PharmaTimes here: Safety First: Drug safety should be top-of-mind during COVID-19 developments
